FindTrial
Sign In

Placebo to Pembrolizumab

DRUG3 trials

Sponsors

Merck Sharp & Dohme LLC

Conditions

Cervical CancerLocally Advanced Cervical CancerUrinary Bladder Neoplasms

Phase 3

Efficacy and Safety Study of First-line Treatment With Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Women With Persistent, Recurrent, or Metastatic Cervical Cancer (MK-3475-826/KEYNOTE-826)
CompletedNCT03635567
Merck Sharp & Dohme LLCCervical Cancer
Start: 2018-10-25End: 2024-06-04Updated: 2026-02-04
Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Chemoradiotherapy (CRT) Versus CRT Alone in Muscle-invasive Bladder Cancer (MIBC) (MK-3475-992/KEYNOTE-992)
Active, not recruitingNCT04241185
Merck Sharp & Dohme LLCUrinary Bladder Neoplasms
Start: 2020-05-19End: 2031-11-01Target: 520Updated: 2024-11-25
A Randomized, Phase 3, Double-Blind Study of Chemoradiotherapy With or Without Pembrolizumab for the Treatment of High-risk, Locally Advanced Cervical Cancer (KEYNOTE-A18 / ENGOT-cx11/GOG-3047)
Active, not recruitingCTIS2022-501972-25-00
Merck Sharp & Dohme LLCLocally Advanced Cervical Cancer
Start: 2020-04-06Target: 273Updated: 2025-11-26

Related Papers

Pembrolizumab plus chemotherapy with or without bevacizumab in East Asian participants with persistent, recurrent, or metastatic cervical cancer: results from KEYNOTE-826 final analysis.
2025-07-01
Cost-Effectiveness of Pembrolizumab as First-Line Treatment in Patients with Persistent, Recurrent, or Metastatic Cervical Cancer in the United States.
2024-11-057 citations
Pembrolizumab plus chemotherapy for advanced and recurrent cervical cancer: final analysis according to bevacizumab use in the randomized KEYNOTE-826 study.
2024-10-1022 citations
Phase 3 KEYNOTE-992 study of pembrolizumab plus chemoradiotherapy versus placebo plus chemoradiotherapy in patients with muscle-invasive bladder cancer (MIBC).
Journal of Clinical Oncology2024-01-2910 citations
Phase I Trial of First-line Bintrafusp Alfa in Patients with Locally Advanced or Persistent/Recurrent/Metastatic Cervical Cancer
Clinical Cancer Research2024-01-028 citations
Pembrolizumab or Placebo Plus Chemotherapy With or Without Bevacizumab for Persistent, Recurrent, or Metastatic Cervical Cancer
JAMA Oncology2023-12-1442 citations
#67 Pembrolizumab + chemotherapy for first-line treatment of patients with persistent, recurrent, or metastatic cervical cancer: bevacizumab subgroup analysis based on protocol-specified final overall survival results of KEYNOTE-826
2023-09-015 citations
#1121 KEYNOTE-826: final overall survival results from a randomized, double-blind, phase 3 study of pembrolizumab + chemotherapy vs placebo + chemotherapy for first-line treatment of persistent, recurrent, or metastatic cervical cancer
2023-09-012 citations
KEYNOTE-826: Final overall survival results from a randomized, double-blind, phase 3 study of pembrolizumab + chemotherapy vs placebo + chemotherapy for first-line treatment of persistent, recurrent, or metastatic cervical cancer.
Journal of Clinical Oncology2023-06-0116 citations
Health-related quality of life with pembrolizumab or placebo plus chemotherapy with or without bevacizumab for persistent, recurrent, or metastatic cervical cancer (KEYNOTE-826): a randomised, double-blind, placebo-controlled, phase 3 trial.
2023-03-0346 citations
41 External reproducibility of PD-L1 IHC 22C3 pharmDx for cervical cancer at CPS ≥ 1 and CPS ≥ 10
Regular and Young Investigator Award Abstracts2022-11-011 citations
Abstract CT564: KEYNOTE-992: A randomized phase 3 trial of pembrolizumab versus placebo in patients with muscle-invasive bladder cancer receiving concurrent chemoradiotherapy
Cancer Research2022-06-153 citations
Pembrolizumab + chemotherapy in patients with persistent, recurrent, or metastatic cervical cancer: Subgroup analysis of KEYNOTE-826.
Journal of Clinical Oncology2022-06-0112 citations
58 KEYNOTE-826: Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for persistent, recurrent, or metastatic cervical cancer
2021-10-01
Pembrolizumab for Persistent, Recurrent, or Metastatic Cervical Cancer
New England Journal of Medicine2021-09-18918 citations
Pembrolizumab (pembro) plus chemoradiotherapy (CRT) versus placebo plus CRT for patients (pts) with muscle-invasive bladder cancer (MIBC): The phase III KEYNOTE-992 study.
Journal of Clinical Oncology2021-02-201 citations
Phase III study of pembrolizumab (pembro) plus chemoradiotherapy (CRT) versus CRT alone for patients (pts) with muscle-invasive bladder cancer (MIBC): KEYNOTE-992.
Journal of Clinical Oncology2020-05-2014 citations
393 Keynote-826: a phase 3, randomized, double-blind, placebo-controlled study of pembrolizumab plus chemotherapy for first-line treatment of persistent, recurrent, or metastatic cervical cancer
2019-09-012 citations
KEYNOTE-826: A phase 3, randomized, double-blind, placebo-controlled study of pembrolizumab plus chemotherapy for first-line treatment of persistent, recurrent, or metastatic cervical cancer.
Journal of Clinical Oncology2019-05-2011 citations